Press coverage about Heska (NASDAQ:HSKA) has been trending somewhat positive on Tuesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Heska earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 44.71036039376 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of equities analysts recently weighed in on HSKA shares. Sidoti upgraded shares of Heska from a “neutral” rating to a “buy” rating and set a $94.00 price objective for the company in a report on Monday. Aegis restated a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Raymond James Financial restated a “buy” rating on shares of Heska in a report on Monday, December 4th. BidaskClub upgraded shares of Heska from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, B. Riley restated a “hold” rating and issued a $96.50 price objective on shares of Heska in a report on Friday, October 27th. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $110.08.

Heska (HSKA) traded up $1.91 during trading hours on Tuesday, reaching $74.00. 9,003 shares of the company’s stock were exchanged, compared to its average volume of 57,521. Heska has a fifty-two week low of $69.00 and a fifty-two week high of $115.00. The company has a market cap of $518.44, a P/E ratio of 38.19, a PEG ratio of 1.88 and a beta of 0.67.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of Heska stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the sale, the insider now owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 14.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/06/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-heska-hska-stock-price.html.

Heska Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Insider Buying and Selling by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.